Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02211560 · ClinicalTrials.gov registry record · NA
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
A NA study, sponsored by Enzymotec.
- Terminated
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT02211560 is a NA study that was terminated before completion, run by Enzymotec. The registered enrollment target is 97 participants.
The verdict
NCT02211560, a NA study, was terminated before completion, sponsored by Enzymotec.
- TERMINATED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
Interventions
- OTHER Placebo
- OTHER Phosphatidylserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-12-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02211560
The ClinicalTrials.gov registry entry for NCT02211560 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enzymotec, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02211560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02211560 about?
NCT02211560 is a clinical study titled "Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment". The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
What is the current status of trial NCT02211560?
This trial is currently terminated. It is a NA study. The enrollment target is 97 participants. The study started on 2014-09. Estimated completion is 2017-12-25.
What interventions are being tested in trial NCT02211560?
The interventions under investigation include: Placebo (OTHER), Phosphatidylserine (OTHER).
Who is sponsoring clinical trial NCT02211560?
This trial is sponsored by Enzymotec, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.